medical-devices is the sole category represented across all 1 tracked stories. Danilo D’Alessandro is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ClearPoint Neuro
medical-devices is the sole category represented across all 1 tracked stories. Danilo D’Alessandro is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.8 for that window. We currently track 1 Healthcare story that mention ClearPoint Neuro, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ClearPoint Neuro. Shared-story counts are live from our verified record — not editorial picks.
ClearPoint Neuro reported a 17.8% year-over-year revenue increase for 2025, reaching $37 million, bolstered by the acquisition of Eris Holdings and growth in its biologics segment. Despite rising operational expenses and integration costs, the company demonstrated strong momentum in its neurosurgery navigation and drug delivery platforms.